United Therapeutics Corporation (UTHR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,483 | 1,686 | 1,936 | 2,328 | 2,877 | 3,183 | 3,155 | 3,147 |
| Operating profit | $m | 1,517 | 1,403 | ||||||
| Net profit | $m | 515 | 476 | 727 | 985 | 1,195 | 1,335 | 1,311 | 1,252 |
| EPS reported | $ | 27.86 | 27.91 | ||||||
| Operating cashflow per share | $ | 35.24 | 39.56 | ||||||
| Capex per share | $ | 11.75 | 13.90 | ||||||
| FCF per share | $ | 23.49 | 25.66 | ||||||
| Free cash flow | $m | 1,041 | 1,093 | ||||||
| Net debt | $m | -1,557 | -2,662 | ||||||
| Book value equity | $m | 7,096 | 6,400 | ||||||
| Book value per share | $ | 148.1 | 139.7 | ||||||
| Number of shares | m | 47.9 | 45.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 17.49 | 17.04 | ||||||
| P/B LTM | x | 3.04 | 3.37 | ||||||
| P/S LTM | x | 6.78 | 6.84 | ||||||
| P/FCF LTM | x | 20.74 | 19.75 | ||||||
| EV/EBITDA LTM | x | 11.03 | 12.14 | ||||||
| EV/Sales LTM | x | 6.30 | 6.56 | ||||||
| Earnings Yield LTM | % | +5.72% | +5.87% | ||||||
| FCF Yield | % | +4.82% | +5.06% | ||||||
| Quality | |||||||||
| ROE | % | +18.81% | +20.18% | ||||||
| ROIC | % | +16.13% | +17.69% | ||||||
| Operating margin | % | +47.67% | +44.49% | ||||||
| Gross margin | % | +87.92% | +86.14% | ||||||
| FCF/Sales | % | +32.70% | +34.65% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +13.07% | +13.27% | ||||||
| Sales Growth YoY | % | +10.61% | +9.63% | ||||||
| Net Income Growth YoY | % | +11.68% | +9.69% | ||||||
| FCF Growth | % | -3.69% | +1.15% | ||||||
| Operating Profit Growth | % | +10.18% | +1.92% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 27.68 | - | ||||||
| Net Debt/EBITDA | x | -0.84 | -1.09 | ||||||
| EBIT/Net interest | x | 77.81 | 116.95 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.22 | -0.42 | ||||||
| Gross debt/equity | x | 0.01 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
United Therapeutics Corporation (UTHR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free